⚗️ Time-Dependent Enzyme Inhibition Simulator

Curved Progress Traces — The First Clue That an Inhibitor Is Not at Equilibrium

The starting observation of every time-dependent inhibition (TDI) study is deceptively simple: a continuous enzyme assay whose product-formation trace bends. For a classical fast-equilibrium competitive or noncompetitive inhibitor, product accumulates linearly with time once the E+I⇌EI equilibrium is established within the assay dead time (typically <5–10 s for diffusion-limited binding). But for a growing class of pharmacologically important inhibitors — including many covalent kinase inhibitors, cathepsin K inhibitors, and slow-onset protease inhibitors — the enzyme-inhibitor complex itself evolves after formation, and the progress curve visibly curves downward from an initial fast rate v_i toward a slower steady-state rate v_s.

• 40 µM: Substrate concentration (held near Km throughout dataset)
• 10 s: Continuous read interval (fluorogenic AMC/AFC readout, 30–60 min)
• ~12 s: Mixing dead time (stopped-flow or plate-reader injector)
• F-test, p<0.01: Curvature test (2-phase vs. linear regression)

Assay design: isolating the time-dependent signature from noise

A typical TDI progress-curve experiment uses a model protease or kinase (e.g., a caspase cleaving Ac-DEVD-AMC, or cathepsin K cleaving Z-FR-AMC) at a substrate concentration close to Km so that substrate depletion over the assay window stays below ~15%, keeping the underlying steady-state kinetics quasi-constant. Enzyme is added last to initiate the reaction directly in the presence of inhibitor (no pre-incubation) across a dilution series spanning roughly 0.1–5× the expected Ki, plus a DMSO/vehicle-only control defining v_0, the uninhibited rate.

Fluorescence or absorbance is recorded continuously at 5–15 s intervals for 30–60 minutes on a plate reader or stopped-flow instrument. For a fast-binding inhibitor, each trace is a straight line from t=0, and a plot of the resulting steady rates against [I] simply yields IC50/Ki by standard dose-response fitting. For a time-dependent inhibitor, each trace instead shows an initial, steeper phase (rate v_i, reflecting only the rapidly formed low-affinity EI encounter complex) that decays smoothly into a shallower terminal phase (rate v_s, reflecting the tighter, slowly formed EI* complex). The curvature becomes more pronounced — and v_s drops further below v_i — as [I] increases, because higher inhibitor concentrations drive the initial binding equilibrium further toward EI, accelerating the observed approach to the new, tighter steady state.

A critical control is distinguishing genuine mechanism-based slow binding from artifacts: enzyme instability (progressive loss of activity independent of inhibitor, checked with vehicle-only traces), inner-filter/fluorophore inhibition at high inhibitor concentration, and substrate depletion mimicking curvature. Analysts typically fit both a straight line and the full four-parameter exponential model (below) to every trace and use an extra-sum-of-squares F-test; a statistically preferred 2-phase fit (p<0.01) across a concentration series, with the degree of curvature scaling with [I], is the operational definition of time-dependent inhibition worth carrying into full kinetic analysis.

Fitting the Integrated Rate Equation — Recovering v_i, v_s, and k_obs

Once curvature is confirmed, every individual progress curve is fit by nonlinear regression to the closed-form integrated rate law for slow-onset inhibition. This single equation compresses an entire time-course into three biologically meaningful numbers per inhibitor concentration: how fast the enzyme starts (v_i), how slow it ends up (v_s), and how quickly it gets there (k_obs) — the raw material for every mechanistic conclusion that follows.

• 4-parameter: Fit equation (v_i, v_s, k_obs, offset d)
• 10⁻⁴–10⁻¹ s⁻¹: Typical k_obs range (span of measurable slow-binding rates)
• Prism / KinTek: Software (global nonlinear least-squares or numerical ODE fit)
• n≥3 per [I]: Replicate design (independent enzyme preps)

The Morrison/Duggleby integrated equation and global fitting strategy

The standard model fit to each trace is P(t) = v_s·t + [(v_i − v_s)/k_obs]·(1 − e^(−k_obs·t)) + d, where d is a small vertical offset absorbing dead-volume product formed before the first read. Fitting proceeds by nonlinear least squares (Levenberg–Marquardt), typically in GraphPad Prism or, for more complex or multi-step mechanisms, by numerical integration of the full differential rate equations in KinTek Explorer, which avoids assuming any closed-form solution and instead simulates E, I, EI, EI*, S, and P simultaneously and optimizes the microscopic rate constants directly against the raw fluorescence traces.

A key subtlety arises when the inhibitor concentration approaches or falls below the enzyme concentration used in the assay (common for very tight, sub-nanomolar Ki* inhibitors): free [I] can no longer be approximated as constant and equal to total [I], because a significant fraction is sequestered in EI/EI*. In that tight-binding regime the simple exponential fit is replaced by the Morrison quadratic (tight-binding) equation, which explicitly accounts for ligand depletion, or by numerical simulation. Ignoring this regime systematically underestimates potency — a common pitfall when comparators include sub-nM tool compounds.

Global fitting — simultaneously fitting all [I] traces with shared parameters for v_0, Km, and the mechanistic rate constants (k_on, k_off, k5, k6) rather than fitting each curve independently — is now standard practice because it uses the full information content of the dataset and propagates realistic confidence intervals onto the mechanistic constants rather than onto derived, per-curve v_i/v_s/k_obs triplets. Quality control requires R²>0.98 per trace, randomly scattered residuals (no systematic curvature left unfit), and k_obs standard errors below ~15% of the fitted value; traces failing these criteria are usually symptomatic of enzyme instability or an assay window too short to capture the terminal steady-state phase.

The kobs Replot — Diagnosing One-Step vs. Two-Step Slow-Binding Mechanisms

The single most information-dense plot in TDI kinetics is k_obs replotted against [I]. Its shape alone distinguishes fundamentally different molecular mechanisms of slow binding, and its slope, intercept, and asymptote directly yield the microscopic rate and equilibrium constants that govern how tightly — and how slowly — an inhibitor engages its target.

• k_obs linear: Scheme A (one-step) (k_obs = k_on[I] + k_off)
• k_obs hyperbolic: Scheme B (two-step) (saturates at k5 + k6)
• 0.045 / 0.00058 s⁻¹: Fitted k5 / k6 (isomerization forward/reverse)
• 850 → 12 nM: Ki → Ki* tightening (≈71-fold potency gain via isomerization)

Reading mechanism directly from replot geometry

Three canonical schemes dominate TDI literature, each leaving a distinct fingerprint on the k_obs vs [I] replot:

Scheme A — one-step slow binding (E + I → EI, no subsequent isomerization, but binding itself is intrinsically slow, e.g. due to a conformational gate): k_obs = k_on·[I] + k_off. The replot is a straight line; the slope is the true bimolecular association rate constant k_on (often 10³–10⁵ M⁻¹s⁻¹, far below diffusion-limited ~10⁸ M⁻¹s⁻¹, reflecting a required protein or ligand conformational change before binding), and the y-intercept is k_off, from which Ki = k_off/k_on.

Scheme B — two-step induced-fit/conformational-selection binding (E + I ⇌ EI ⇌ EI*): a rapid-equilibrium encounter complex EI (governed by Ki = k2/k1, typically diffusion-limited on-rate) is followed by a slow, often intramolecular isomerization to a tighter complex EI* with forward rate k5 and reverse rate k6. Here k_obs = k6 + k5·[I]/(Ki·(1+[S]/Km) + [I]) — a rectangular hyperbola in [I] that saturates at k_obs,max = k5 + k6 as [I]→∞ and has y-intercept k6. This is the shape simulated in the plot at left: note the pronounced curvature at low [I] transitioning to a plateau above roughly 3–5× Ki. From the fitted asymptote and intercept, the overall tight-binding constant follows as Ki* = Ki·k6/(k5+k6) — in this system, 850 nM · 0.00058/(0.045+0.00058) ≈ 12 nM, a ~71-fold tightening driven entirely by the isomerization step rather than the initial encounter affinity.

Scheme C — covalent, irreversible inactivation (E + I ⇌ EI →(k_inact) E–I, no measurable k6): k_obs increases hyperbolically with [I] but never plateaus at a true reversible asymptote; instead it approaches k_inact, and potency is reported as the ratio k_inact/KI (analogous to a bimolecular efficiency constant) rather than a true Ki, because activity is never fully recovered by dilution. Distinguishing Scheme B from Scheme C requires the jump-dilution reversibility test performed in Stage 5. Model selection in practice uses Akaike Information Criterion (AICc) comparison between the linear and hyperbolic fits together with visual inspection for a discernible plateau within the tested [I] range — extending the concentration range to ≥10× the apparent Ki is often necessary to unambiguously resolve the asymptote.

IC50 Shift with Pre-Incubation Time — A Simple, Diagnostic Screening Assay

While full progress-curve analysis delivers the complete mechanistic picture, medicinal chemistry teams need a fast, scalable screen to flag time-dependent behavior across hundreds of analogs. The pre-incubation IC50 shift assay does exactly this: enzyme and inhibitor are held together for a variable pre-incubation period before a brief substrate pulse measures initial velocity, and IC50 is plotted as a function of that pre-incubation time.

• ~620 nM: IC50 at t=0 min (no pre-incubation, rapid-equilibrium Ki regime)
• ~15 nM: IC50 at t=60 min (approaches Ki* asymptote)
• ~41-fold: Fold-shift observed (>3–5× shift flags true TDI)
• <2 min: Read window post-substrate (keeps turnover <10%, avoids further binding)

Protocol design and interpretation of the shift plateau

Enzyme is combined with a dilution series of inhibitor in assay buffer and incubated at 25–37°C for a defined time — typically 0, 5, 15, 30, and 60 minutes across parallel plates or wells. At the end of each pre-incubation period, substrate is spiked in at a saturating pulse and the initial rate is captured over a short window (often <2 minutes, or read immediately by stopped-flow) chosen to be short relative to k_obs⁻¹ so that essentially no further EI→EI* isomerization occurs during the measurement itself — the read reports the instantaneous inhibitory state established during pre-incubation, not a new time-dependent process layered on top.

At each pre-incubation time, the initial-rate data across the inhibitor dilution series are fit to a four-parameter logistic (Hill) dose-response to extract an apparent IC50. For a fast-equilibrium inhibitor, IC50 is essentially invariant with pre-incubation time (typically <2-fold variation, within assay noise) because equilibrium is reached within the mixing dead time regardless of how long you wait afterward. For a genuine time-dependent inhibitor, IC50 falls progressively with increasing pre-incubation time as more of the population converts from the loosely bound EI state to the tightly bound EI* state, and — critically — the IC50 vs. time curve plateaus once pre-incubation exceeds roughly 5/k_obs, at an asymptotic value reflecting Ki* rather than Ki. The magnitude of the total fold-shift (IC50 at t=0 divided by the plateau IC50) is a convenient potency-tightening metric reported directly in SAR tables; shifts below ~2–3-fold are usually within experimental noise, while shifts of 10–100-fold (as simulated here, ~41-fold) are unambiguous evidence of a two-step slow-binding or covalent mechanism and materially change how the compound's in vivo dose and dosing interval should be modeled — an assay run without pre-incubation would systematically underestimate true achievable potency by more than an order of magnitude.

Jump Dilution and Residence Time — From k_off to Predicted In Vivo Durability

The final, decisive experiment both confirms reversibility and delivers the parameter increasingly used to rank drug candidates ahead of binding affinity alone: residence time, τ = 1/k_off. A pre-formed, saturating enzyme-inhibitor complex is rapidly and massively diluted into a substrate-rich buffer, and the slow recovery of catalytic activity is tracked directly, giving a first-principles measurement of how long the complex survives once free inhibitor is effectively removed.

• 100×: Dilution factor (drops free [I] far below Ki*)
• 5.8×10⁻⁴ s⁻¹: Fitted k_off (k6) (reverse isomerization rate)
• ~19.9 min: Residence time (t½) (ln2 / k_off)
• >90% recovery: Reversibility check (confirms non-covalent EI* (Scheme B))

Jump-dilution protocol and the pharmacological meaning of residence time

The complex is first pre-formed by incubating enzyme with a high, saturating concentration of inhibitor (typically ≥20× Ki*) for a period well beyond 5/k_obs, ensuring near-complete conversion of EI to the tight EI* state. This mixture is then diluted 50- to 200-fold directly into an assay well containing substrate at Km, dropping the free inhibitor concentration to well below Ki (often below Ki*), so that any inhibitor that dissociates is diluted away rather than rebinding. Product formation is monitored continuously over the following minutes to hours; a control lacking pre-incubation (enzyme added directly to the diluted, low inhibitor concentration) defines the fully active, uninhibited rate.

For a reversible slow-binding inhibitor, activity recovers slowly following A(t) = A_final − (A_final − A_initial)·e^(−k_off·t), and fitting this trace yields k_off = k6 directly and independently of the forward isomerization rate k5 measured earlier — an internal consistency check against the kobs replot asymptote. If instead little or no activity recovers even after extended dilution (hours), the inhibitor is covalent/irreversible (Scheme C), and k_off is operationally zero; residence time is then effectively infinite until new enzyme is synthesized in vivo.

Residence time, τ = 1/k_off (here 1/5.8×10⁻⁴ s⁻¹ ≈ 1724 s ≈ 28.7 min, giving a half-life of dissociation t½ = ln2/k_off ≈ 19.9 min), has become a first-class optimization parameter in drug discovery because target engagement in vivo depends on how long the drug-target complex persists relative to the pharmacokinetic clearance of free drug — a long residence time can sustain target inhibition well after plasma drug concentration has fallen below Ki, decoupling efficacy duration from exposure and enabling reduced dosing frequency.

The cathepsin K inhibitor odanacatib is a textbook two-step slow-binding inhibitor: a rapid-equilibrium encounter complex (Ki in the low nanomolar range) isomerizes over minutes to a markedly tighter EI* complex with sub-nanomolar Ki* and a measured residence time exceeding several hours. That extended residence time — far outlasting the compound's plasma half-life — was central to the rationale for once-weekly oral dosing in clinical development, illustrating how a Stage 5-style jump-dilution measurement can directly justify a clinical dosing regimen rather than remaining a purely academic kinetic parameter.